Steel Therapeutics Overview

  • Year Founded
  • 2020

Year Founded

  • Status
  • Private

  • Employees
  • 3

Employees

  • Latest Deal Type
  • Later Stage VC

  • Latest Deal Amount
  • $2M

  • Investors
  • 2

Steel Therapeutics General Information

Description

Developer of pharmaceutical therapies intended to increase access to compounded medications through FDA-approved products. The company builds retail compounding programs and identifies both high-impact drug candidates and innovative delivery systems, enabling healthcare professionals to analyze scientific literature and provide information regarding novel drug target hypotheses.

Contact Information

Ownership Status
Privately Held (backing)
Financing Status
Venture Capital-Backed
Corporate Office
  • 290 Cambridge Way
  • North Liberty, IA 52317
  • United States
+1 (612)
Primary Industry
Drug Discovery
Other Industries
Biotechnology
Vertical(s)
Corporate Office
  • 290 Cambridge Way
  • North Liberty, IA 52317
  • United States
+1 (612)

Steel Therapeutics Timeline

2023202420252026
Financing RoundCaptured Employee CountEstimated Employee Growth

Want detailed data on 11M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

Steel Therapeutics Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
6. Later Stage VC 22-Jul-2025 $2M Completed Generating Revenue
5. Early Stage VC 05-Dec-2024 Completed Generating Revenue
4. Early Stage VC 01-Apr-2022 Completed Generating Revenue
3. Early Stage VC (Series A) Completed Generating Revenue
2. Early Stage VC 02-Jun-2021 $378K $378K Completed Generating Revenue
1. Accelerator/Incubator 01-Jan-2020 Completed Startup
To view Steel Therapeutics’s complete valuation and funding history, request access »

Steel Therapeutics Cap Table

Stock # of Shares
Authorized
Par Value Dividend Rate (%) Original
Issue Price
Liquidation Liquidation
Pref. Multiple
Conversion Price % Owned
Seed-2
Seed-1
Seed 683,106 $0.001000 $2.12 $2.12 1x $2.12 12.35%
To view Steel Therapeutics’s complete cap table history, request access »

VC Exit Predictor

See how our proprietary methodology utilizes historical data sets to synthesize the likelihood of an acquisition, IPO, or no exit event. Get a detailed look at the calculations behind our predictions.

Opportunity Score

Calculated using Exit Type probabilities, the company’s stage, and PitchBook’s historical returns data.

Exit Type

Evaluates the likelihood of a successful exit for investors, and the most likely exit type.

Steel Therapeutics Comparisons

Description
Primary
Industry
HQ Location
Employees
Total Raised
Post Valuation
Last
Financing
Details
Developer of pharmaceutical therapies intended to increase access to compounded medications through FDA-approved product
Drug Discovery
North Liberty, IA
3 As of 2026

Woburn, MA
 
Add Comparison

PitchBook’s comparison feature gives you a side-by-side look at key metrics for similar companies. Personalize which data points you want to see and create visualizations instantly.

Request a free trial

Steel Therapeutics Competitors (1)

One of Steel Therapeutics’s competitors is Azurity Pharmaceuticals, a Private Equity-Backed company based in Woburn, MA.

Company Name Financing Status Location Employees Total Raised Last Financing Date/Type Last Financing Amount
Azurity Pharmaceuticals Private Equity-Backed Woburn, MA
You’re viewing 1 of 1 competitors. Get the full list »

Steel Therapeutics Patents

Steel Therapeutics Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
AU-2022252406-A1 Topical wipe containing nifedipine and lidocaine Pending 01-Apr-2021
CA-3213764-A1 Topical wipe containing nifedipine and lidocaine Pending 01-Apr-2021
EP-4312984-A1 Topical wipe containing nifedipine and lidocaine Pending 01-Apr-2021
EP-4312984-A4 Topical wipe containing nifedipine and lidocaine Pending 01-Apr-2021
US-20240156756-A1 Topical wipe containing nifedipine and lidocaine Pending 01-Apr-2021 A61K31/167
To view Steel Therapeutics’s complete patent history, request access »

Steel Therapeutics Signals

Growth Rate

Weekly
Growth
Weekly Growth

Size Multiple

Median
Size Multiple

Key Data Points

Similarweb Unique Visitors

Majestic Referring Domains

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

Steel Therapeutics Investors (2)

Investor Name Investor Type Holding Investor Since Participating Rounds
ISA Ventures Venture Capital Minority
New Bohemian Innovation Collaborative Accelerator/Incubator
To view Steel Therapeutics’s complete investors history, request access »

Steel Therapeutics FAQs

  • When was Steel Therapeutics founded?

    Steel Therapeutics was founded in 2020.

  • Where is Steel Therapeutics headquartered?

    Steel Therapeutics is headquartered in North Liberty, IA.

  • What is the size of Steel Therapeutics?

    Steel Therapeutics has 3 total employees.

  • What industry is Steel Therapeutics in?

    Steel Therapeutics’s primary industry is Drug Discovery.

  • Is Steel Therapeutics a private or public company?

    Steel Therapeutics is a Private company.

  • What is Steel Therapeutics’s current revenue?

    The current revenue for Steel Therapeutics is .

  • How much funding has Steel Therapeutics raised over time?

    Steel Therapeutics has raised $9.1M.

  • Who are Steel Therapeutics’s investors?

    ISA Ventures and New Bohemian Innovation Collaborative have invested in Steel Therapeutics.

  • Who are Steel Therapeutics’s competitors?

    Azurity Pharmaceuticals is a competitor of Steel Therapeutics.

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read more
  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process